XML 23 R12.htm IDEA: XBRL DOCUMENT
v3.26.1

Goodwill and Intangible Assets | 3 Months Ended
--- | ---
Mar. 31, 2026
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Intangible Assets | Goodwill and Intangible Assets The following table summarizes the carrying amounts of goodwill at March 31, 2026 and December 31, 2025 (in thousands):
|  | Goodwill Carrying Amount
Balance as of December 31, 2024 |  | $ | 522,766 |
Acquired goodwill(1) |  | 5,078 |
Impairment charges(2) |  | (3,500) |
Balance as of December 31, 2025 |  | $ | 524,344 |
Acquired goodwill adjustment(1) |  | (349) |
Balance as of March 31, 2026 |  | $ | 523,995 |
_________________ (1) In connection with the acquisition of Pathline, the Company recognized $5.1 million of goodwill during the year ended December 31, 2025 and an adjustment of $0.3 million during the three months ended March 31, 2026, reflecting the allocation of the purchase price to the identifiable assets acquired and liabilities assumed. Please refer to Note 3. Acquisitions and Disposals for further information about the acquisition of Pathline. (2) In connection with the classification of the Trapelo assets as held for sale, the Company recognized an impairment charge of $3.5 million to write down the carrying value of the disposal group to its estimated fair value less costs to sell. Please refer to Note 3. Acquisitions and Disposals for further information about the sale of Trapelo. Intangible assets consisted of the following (in thousands):
|  |  |  | March 31, 2026
|  | Amortization Period (years) |  | Cost |  | Accumulated Amortization |  | Net
Customer Relationships |  | 7 - 15 |  | $ | 144,301 |  |  | $ | 87,957 |  |  | $ | 56,344 |
Developed Technology |  | 10 - 15 |  | 276,825 |  |  | 88,327 |  |  | 188,498 |
Trademarks |  | 15 |  | 30,261 |  |  | 9,655 |  |  | 20,606 |
Trademark - Indefinite lived |  | — |  | 13,447 |  |  | — |  |  | 13,447 |
Total |  |  |  | $ | 464,834 |  |  | $ | 185,939 |  |  | $ | 278,895 |
|  |  |  | December 31, 2025
|  | Amortization Period (years) |  | Cost |  | Accumulated Amortization |  | Net
Customer Relationships(1) |  | 7 - 15 |  | $ | 144,301 |  |  | $ | 85,441 |  |  | $ | 58,860 |
Developed Technology(2) |  | 10 - 15 |  | 276,825 |  |  | 83,714 |  |  | 193,111 |
Trademarks(3) |  | 15 |  | 30,261 |  |  | 9,151 |  |  | 21,110 |
Trade Name |  | 2.5 |  | 2,584 |  |  | 2,584 |  |  | — |
Trademark - Indefinite lived |  | — |  | 13,447 |  |  | — |  |  | 13,447 |
Total |  |  |  | $ | 467,418 |  |  | $ | 180,890 |  |  | $ | 286,528 |
_________________ (1) Includes $1.2 million of acquired client relationships related to Pathline. Please refer to Note 3. Acquisitions and Disposals for further information about the acquisition of Pathline. (2) Includes an impairment loss of $10.5 million on InVisionFirst®-Lung developed technology and an adjustment of $12.4 million related to the classification of Trapelo as held for sale. Please refer to Note 3. Acquisitions and Disposals for further information about the disposal of Trapelo assets. (3) Includes an impairment loss of $0.9 million on InVisionFirst®-Lung trademarks. The Company records amortization expense within cost of revenue and general and administrative expense on the Consolidated Statement of Operations. The following table summarizes the amortization expense for the three months ended March 31, 2026 and 2025 (in thousands):
|  | Three Months Ended March 31, |  |
|  | 2026 |  | 2025 |  |  |  |
Amortization of intangibles included in cost of revenue |  | $ | 4,614 |  |  | $ | 4,910 |  |  |  |  |
Amortization of intangibles included in general and administrative expenses |  | 3,019 |  |  | 3,452 |  |  |  |
Total amortization of intangibles |  | $ | 7,633 |  |  | $ | 8,362 |  |  |  |  |
The estimated amortization expense related to amortizable intangible assets for each of the following periods as of March 31, 2026 is as follows (in thousands):
Remainder of 2026 | $ | 22,900 |
2027 | 29,983 |
2028 | 29,983 |
2029 | 29,983 |
2030 | 29,530 |
Thereafter | 123,069 |
Total | $ | 265,448 |
InVisionFirst®-Lung Impairment During the year ended December 31, 2025, the Company recorded impairment charges of $11.4 million and an inventory write-off of $0.4 million associated with InVisionFirst®-Lung, a legacy diagnostic test. Impairment charges consisted of a $10.5 million loss on developed technology and a $0.9 million loss on trademarks. The impairment charge and inventory write-off were included within impairment charges on the Consolidated Statements of Operations. There were no such costs for the three months ended March 31, 2026.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration